Cargando…
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models
This study investigated the antitumour effects of two dual mTOR/PI3K inhibitors, gedatolisib (WYE-129587/PKI-587/PF-05212384) and PF-04691502 against a panel of six human patient derived ovarian cancer xenograft models. Both dual mTOR/PI3K inhibitors demonstrated antitumour activity against all xeno...
Autores principales: | Langdon, Simon P., Kay, Charlene, Um, In Hwa, Dodds, Michael, Muir, Morwenna, Sellar, Grant, Kan, Julie, Gourley, Charlie, Harrison, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904563/ https://www.ncbi.nlm.nih.gov/pubmed/31822716 http://dx.doi.org/10.1038/s41598-019-55096-9 |
Ejemplares similares
-
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
por: Wainberg, Zev A., et al.
Publicado: (2017) -
ABCB1 and ABCG2 restricts the efficacy of gedatolisib (PF-05212384), a PI3K inhibitor in colorectal cancer cells
por: Liu, Changfu, et al.
Publicado: (2021) -
Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX()
por: Iezzi, Alice, et al.
Publicado: (2016) -
Evaluation of a Dual PI3K/mTOR Inhibitor PF-04691502 against Bladder Cancer Cells
por: Shang, Xiaosong, et al.
Publicado: (2022) -
PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors
por: Chow, Zeta, et al.
Publicado: (2021)